Trial
NCT02850874
HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Wake Forest University Health Sciences
Collaborators
—
Condition
Pancreatic Neoplasms
Intervention
Hyperthermic intraperitoneal chemotherapy
Why stopped
no accrual rate
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-04-27